3 Companies Priced for a Buyout

source of cost-cutting, making it the kind of flaw that can sweeten a deal rather than sour it. King Pharmaceuticals EV/Ebitda: 3.9 Bristol, Tenn.-based King Pharmaceuticals (KG) might need 'its own Thrombin to stop bleeding,' wrote investment bank...